Aurobindo Pharma Ltd sells its step down subsidiary in Australia to Eris Pharmaceuticals (Australia) Pty Ltd



  • Aurobindo executes on its strategy to focus on core high-value business in US, Europe and Key Emerging Markets.
  • Eris broadens its offering of generic molecules to Australian pharmacies

April 10, 2015, Sydney, Australia:  Aurobindo Pharma Limited (BSE:NSE Auropharma) (“Aurobindo”) today announced the sale of its step down subsidiary Aurobindo Pharma Australia Pty Ltd (“Aurobindo Australia”), with operations in Australia and New Zealand, to Eris Pharmaceuticals Australia Pty Ltd (“Eris”), an Australian pharmaceutical company whose products are sold in the Middle East, North Africa, CIS and Balkans countries. The subsidiary was not contributing any profit to Aurobindo.

As a result of this acquisition of marketing authorisations for prescription and over-the-counter (“OTCs”) products through its ownership of Aurobindo Australia, Eris will become a significant generic pharmaceutical company in Australia. The Eris product portfolio offered to Australian pharmacists includes prescription generics, OTCs, dermo-cosmetic and other healthcare products.

Aurobindo is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialised branded pharmaceutical products. In line with its focus on priority markets, Aurobindo is focused on the sales of its products into the larger pharmaceutical markets in US, Europe and Key Emerging Markets.

Mr. Panos Athanasiou, CEO of Eris, said:  “The purchase of Aurobindo Australia is a significant growth initiative for Eris.  We now are able to offer an extensive product portfolio comprising of quality prescription generics, OTCs and other healthcare products at competitive prices to Australian Pharmacists, particularly where the pharmacists are looking for alternatives other than their traditional suppliers. We are very proud of the growth of Eris both in Australia and across other territories.  This acquisition represents an important step for Eris towards becoming one of the leading suppliers of quality medicines in Australia and New Zealand. The whole Eris team is highly motivated and proud to become a partner of Aurobindo in this region.”

Along with the acquisition, Eris has entered into a Supply and Distribution Agreement with Aurobindo. Eris will continue to sell the Aurobindo generic prescription products and to support the loyal customers of Aurobindo Australia. The company will look forward to expanding its offering to those existing customers of Aurobindo Australia and to new customers from its growing range of prescription generics, OTCs, dermo-cosmetics and other healthcare products.

Counselcorp Lawyers and Corporate Advisers acted as corporate advisers and legal counsel to Eris.

Back To Top

Related Links

Australian Business Unit

The Australian Business Unit covers the needs of the Australian & New Zealand markets.

Learn more »

Overseas Business Unit

The Overseas Business Unit covers the activities and needs of the Emerging markets.

Learn more »

Life in Focus™

Discover Life in Focus™, the new range in Dietary Supplements.

Learn more »